About Us

Xiaowei is a professor of Science, Chemistry and Chemical Biology, and Physics at Harvard University and an Investigator at HHMI. Xiaowei’s lab is known for the development of both MERFISH and STORM for super resolution microscopy. She has won numerous awards including the 2021 Lurie Prize in Biomedical Sciences, 2019 Breakthrough Prize in Life Sciences and the 2019 NAS Award for Scientific Discovery. Xiaowei has been elected to both the National Academy of Sciences and National Academy of Medicine.

David is a leader in scientific innovation and has founded and invested in successful companies for over 20 years; his public companies include Illumina, Quanterix, and 908 Devices and his start-ups include Sherlock Biosciences, Ultivue, and Arbor Biotechnologies. David is a Professor at Brigham and Women’s Hospital and the Wyss Institute, and a faculty member at Harvard Medical School. David has been elected to both the National Academy of Sciences and National Academy of Medicine and was inducted into the National Inventors Hall of Fame in 2019.

Jeffrey is the co-inventor of MERFISH technology, developed in Xiaowei Zhuang’s lab. He is applying MERFISH to the construction of cellular atlases on a wide range of tissues with a particular focus on the interface between host and microbial communities. Jeffrey has his PhD in Physics from UC Berkeley where he developed novel methods for manipulating single molecules. Jeffrey is an Associate Member of the Broad Institute and was named Pew Biomedical Scholar in 2019.

Susan Tousi is Chief Commercial Officer at Illumina, where she leads global sales, commercial operations, and commercial strategy and enablement. Susan combines her extensive general management leadership and deep technical knowledge of Illumina’s product portfolio to ensure the global commercial success of the organization. She is committed to empowering Illumina customers with innovations to further unlock the power of the genome.

Susan has been with Illumina since 2012, and previously led the product development organization as Chief Product Officer. During that time, she was responsible for global engineering, consumables, sequencing applications, IVD, software and informatics development efforts: During this time, she oversaw the most impactful decade of product launches including: HiSeq X, NovaSeq, MiSeq Dx, NextSeq 550Dx/1000/2000, iSeq, VeriSeq NIPT, TSO500, COVIDSeq, DRAGEN, and Illumina Connected Analytics. Additionally, she led the acquisition of Edico Genomics, BlueBee, and Enancio, combined with Illumina’s existing software solutions, these new capabilities enable scalable, seamless, end-to-end software solutions that drive the utilization of genomic data and accelerate the adoption of genomic data in clinical care.

Susan has more than 25 years of R&D and business leadership at Fortune 100 technology companies and within the life sciences industry. Formerly, she was Corporate Vice President and General Manager for Eastman Kodak’s Consumer Inkjet Systems organization. Prior to joining Kodak, Susan was an R&D program manager for Phogenix Imaging LLC, a joint venture start-up of Hewlett-Packard and Kodak. She previously spent 10 years with Hewlett-Packard in technical and management roles. Along with many academic honors, she has received numerous awards in both business and technology. In 2018, Susan was elected to the National Academy of Engineers. Susan was named one of the 50 Top Diverse Leaders for 2020 by the California Diversity Council and is a member of the International Women’s Forum, a global organization of preeminent women of significant and diverse achievement.

Susan holds an MBA degree from UCLA and an Honors BS in Engineering Science and Mechanics from Pennsylvania State University.

Susan serves as an executive trustee at the world renowned La Jolla Playhouse and on the UCSD Jacobs School of Engineering Dean’s Council of Advisors.

Terry pioneered and led the early commercial success of spatial biology and mIF, first as GM for PerkinElmer’s tissue business, and then as President of Akoya Biosciences. Prior to this, Terry led the global adoption of HPV testing for cervical cancer primary screening at Roche Molecular. Terry also has extensive experience in International markets including GM of China and Japan, and Head of International Strategy at Hologic, and Director of Corporate BD APAC at BMS.

Marijn E. Dekkers is founder and chairman of Novalis LifeSciences LLC, an investment and advisory firm for the Life Science industry that he founded in 2017. From 2010-2016, Dr. Dekkers served as CEO of Bayer AG in Leverkusen, Germany. From 2002-2009, he was CEO of Thermo Fisher Scientific in Waltham, MA, USA. He started his career as a research scientist at General Electric’s Corporate R&D Center in Niskayuna, NY, USA.

David is a leader in scientific innovation and has founded and invested in successful companies for over 20 years; his public companies include Illumina, Quanterix, and 908 Devices and his start-ups include Sherlock Biosciences, Ultivue, and Arbor Biotechnologies. David is a Professor at Brigham and Women’s Hospital and the Wyss Institute, and a faculty member at Harvard Medical School. David has been elected to both the National Academy of Sciences and National Academy of Medicine and was inducted into the National Inventors Hall of Fame in 2019.

Mr. Posard brings over 30 years of general management and commercialization experience in the life sciences, therapeutics, and diagnostics industry to the Board of Directors. He is the Founding Principal of Explore DNA, a life sciences executive consulting firm, a position he has held since March 2016. Since 2017, he has provided advisory services to CEOs for several emerging life sciences companies. From February 2017 to April 2018, Mr. Posard served as President and Chief Commercial Officer of GenePeeks, Inc., a genetic research company. From March 2015 to April 2016, he served as Chief Commercial Officer of Trovagene, Inc., a molecular diagnostic biotechnology company. From February 2006 to February 2015, he held various commercial and general management positions at Illumina, Inc., a genomics company focusing on DNA sequencing, including senior executive positions overseeing Global Sales, Marketing, and General Manager of Clinical and Consumer Genomics as well as New and Emerging Markets. Mr. Posard holds a BA degree in Management Science from the University of California, San Diego.

Keith Crandell is a Managing Director and Co-Founder of ARCH Venture Partners, L.P., a global seed, and early-stage venture capital firm focused on innovations in the life and physical sciences. Keith holds an M.B.A. from The University of Chicago (Booth), an M.S. in Chemistry from the University of Texas at Arlington, and a B.S. in Chemistry and Mathematics from St. Lawrence University.